Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17778
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKim, Soo-Hyun-
dc.contributor.authorRedvers, Richard P-
dc.contributor.authorChi, Lap Hing-
dc.contributor.authorLing, Xiawei-
dc.contributor.authorLucke, Andrew J-
dc.contributor.authorReid, Robert C-
dc.contributor.authorFairlie, David P-
dc.contributor.authorBaptista Moreno Martin, Ana Carolina-
dc.contributor.authorAnderson, Robin L-
dc.contributor.authorDenoyer, Delphine-
dc.contributor.authorPouliot, Normand-
dc.date2018-05-21-
dc.date.accessioned2018-05-24T04:32:49Z-
dc.date.available2018-05-24T04:32:49Z-
dc.date.issued2018-05-21-
dc.identifier.citationDisease models & mechanisms 2018; online first: 21 May-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17778-
dc.description.abstractBreast cancer brain metastasis remains largely incurable. While several mouse models have been developed to investigate the genes and mechanisms regulating breast cancer brain metastasis, these models often lack clinical relevance since they require the use of immune-compromised mice and/or are poorly metastatic to brain from the mammary gland. We describe the development and characterisation of an aggressive brain metastatic variant of the 4T1 syngeneic model (4T1Br4) that spontaneously metastasises to multiple organs, but is selectively more metastatic to the brain from the mammary gland than parental 4T1 tumours. By immunohistochemistry, 4T1Br4 tumours and brain metastases display a triple negative phenotype, consistent with the high propensity of this breast cancer subtype to spread to brain. In vitro assays indicate that 4T1Br4 cells have an enhanced ability to adhere to or migrate across a brain-derived endothelial monolayer and greater invasive response to brain-derived soluble factors compared to 4T1 cells. These properties are likely to contribute to the brain-selectivity of 4T1Br4 tumours. Expression profiling and gene set enrichment analyses demonstrate the clinical relevance of the 4T1Br4 model at the transcriptomic level. Pathway analyses implicate tumour-intrinsic immune regulation and vascular interactions in successful brain colonisation, revealing potential therapeutic targets. Evaluation of two histone deacetylase inhibitors, SB939 and 1179.4b, shows partial efficacy against 4T1Br4 metastasis to brain and other sites in vivo and potent radio-sensitising properties in vitro The 4T1Br4 model provides a clinically relevant tool for mechanistic studies and to evaluate novel therapies against brain metastasis.-
dc.language.isoeng-
dc.subject4T1Br4-
dc.subjectBrain metastasis-
dc.subjectBreast cancer-
dc.subjectHistone deacetylase inhibitor-
dc.subjectSyngeneic mouse model-
dc.titleIdentification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis.-
dc.typeJournal Article-
dc.identifier.journaltitleDisease models & mechanisms-
dc.identifier.affiliationMetastasis Research Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia-
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia -
dc.identifier.affiliationMetastasis Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia-
dc.identifier.affiliationDivision of Chemistry and Structural Biology, ARC Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Brisbane, Qld, Australia-
dc.identifier.affiliationDepartment of Gerontology, Federal University of São Carlos, São Carlos, SP, Brazil-
dc.identifier.affiliationDepartment of Pathology, The University of Melbourne, Victoria, Australia-
dc.identifier.affiliationSir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia-
dc.identifier.affiliationMatrix Microenvironment & Metastasis Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia-
dc.identifier.doi10.1242/dmm.034850-
dc.identifier.orcid0000-0002-7039-8638-
dc.identifier.orcid0000-0003-4527-7938-
dc.identifier.orcid0000-0003-0983-3474-
dc.identifier.orcid0000-0002-7856-8566-
dc.identifier.orcid0000-0002-6841-7422-
dc.identifier.orcid0000-0001-8932-5116-
dc.identifier.orcid0000-0002-7654-3445-
dc.identifier.pubmedid29784888-
dc.type.austinJournal Article-
local.name.researcherAnderson, Robin L
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

6
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.